Glaxo gives up some rights on impotence drug

GlaxoSmithKline today said it was giving up some of the rights to its Levitra impotence treatment because the market was not growing quickly enough.

The drugs giant said the growth in sales of Levitra – a competitor to high-profile pill Viagra – had not kept pace with its other blockbuster treatments for illnesses such as asthma and diabetes.